Form 4 for KAPA Kairos Pharma, LTD.
Accepted 2025-11-26 00:00:00 ET · period of report 2025-10-08 · accession 0001493152-25-025203 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-26 | 2025-10-08 | KAPA | Singhvi Rahul | Dir | A - Grant | $0.00 | +19.1K | 49.2K | +63% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | COMMON STOCK | 2025-10-08 | A | A | 19,084 | $0.00 | 49,204 | D | — | — | (F1) Represents 19,084 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date. (F2) Consists of 49,204 RSUs which remain subject to vesting. |